Literature DB >> 8348859

Electrogalvanic stimulation for levator syndrome: how effective is it in the long-term?

T L Hull1, J W Milsom, J Church, J Oakley, I Lavery, V Fazio.   

Abstract

Levator syndrome is a symptom complex of severe pain and pressure in the anorectal area. Electrogalvanic stimulation (EGS) has been proposed as a treatment for this condition. Several reports have described EGS as up to 90 percent "effective" in treating levator syndrome, but the length of follow-up was uncertain or short-term in these studies. The purpose of this study was to examine the long-term benefits of EGS in levator syndrome patients treated at one institution. All patients undergoing EGS for levator syndrome between 1985 and 1991 were studied. Initial complaints, physical examination, number of treatments, procedure tolerance, and long-term benefit were determined through personal interviews and chart reviews. There were 52 patients (63 percent females and 37 percent males) with a median age of 54 years (range, 24-84 years). All patients presented with anorectal pain. Tenderness was localized by examination to the left in 43 percent, to the right in 23 percent, and bilateral in 8.6 percent and was not localized in 2.6 percent. Fifty percent received fewer than four one-hour treatments, 33 percent received four to six treatments, and 17 percent received more than six treatments. Seventy-seven percent felt that the treatment was painless. Follow-up results were as follow: number, 52; percent follow-up, 88; mean follow-up, 28 months (range, 0-71 months); symptoms relieved, 19 percent; partial relief, 24 percent; no relief, 57 percent. Of four patients with a wrong diagnosis, three were ultimately diagnosed with recurrent pelvic cancer and one had an anal fissure. At our institution, EGS was a tolerable treatment, but a substantial number of patients received no benefit. An organic etiology of anorectal pain must always be excluded.

Entities:  

Mesh:

Year:  1993        PMID: 8348859     DOI: 10.1007/bf02048360

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  8 in total

1.  Complications of perineal surgery.

Authors:  James W Ogilvie; Rocco Ricciardi
Journal:  Clin Colon Rectal Surg       Date:  2009-02

Review 2.  Chronic proctalgia and chronic pelvic pain syndromes: new etiologic insights and treatment options.

Authors:  Giuseppe Chiarioni; Corrado Asteria; William E Whitehead
Journal:  World J Gastroenterol       Date:  2011-10-28       Impact factor: 5.742

3.  A pilot randomized trial of levator injections versus physical therapy for treatment of pelvic floor myalgia and sexual pain.

Authors:  Dani Zoorob; Mary South; Mickey Karram; Julie Sroga; Rose Maxwell; Aparna Shah; James Whiteside
Journal:  Int Urogynecol J       Date:  2014-12-20       Impact factor: 2.894

4.  Comparison study between electrogalvanic stimulation and local injection therapy in levator ani syndrome.

Authors:  Duk-Hoon Park; Seo-Gue Yoon; Kuhn Uk Kim; Do Yeon Hwang; Hyun Shig Kim; Jong Kyun Lee; Kwang Yun Kim
Journal:  Int J Colorectal Dis       Date:  2004-10-30       Impact factor: 2.571

Review 5.  Pelvic floor physical therapy for patients with prostatitis.

Authors:  J M Potts; E O'Dougherty
Journal:  Curr Urol Rep       Date:  2000-08       Impact factor: 3.092

6.  Biofeedback is superior to electrogalvanic stimulation and massage for treatment of levator ani syndrome.

Authors:  Giuseppe Chiarioni; Adriana Nardo; Italo Vantini; Antonella Romito; William E Whitehead
Journal:  Gastroenterology       Date:  2010-01-04       Impact factor: 22.682

Review 7.  Frequency, urgency, and pelvic pain: treating the pelvic floor versus the epithelium.

Authors:  Kenneth M Peters; Donna J Carrico
Journal:  Curr Urol Rep       Date:  2006-11       Impact factor: 2.862

8.  Role of three-dimensional endoanal ultrasound in assessing the anal sphincter morphology of female patients with chronic proctalgia.

Authors:  Ya-Hong Xue; Shu-Qing Ding; Yi-Jiang Ding; Li-Qun Pan
Journal:  World J Gastroenterol       Date:  2017-06-07       Impact factor: 5.742

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.